IPCALAB

Ipca Laboratories Share PriceIpca Laboratories

₹1,149.7
16.75 (1.48%)
  • Advice
  • Hold
As on 02 December, 2023 | 20:03 BSE: 524494 NSE: IPCALABISIN: INE571A01038

Ipca Laboratories Performance

Day Range

  • Low 1,123.95
  • High 1,153.00
₹ 1,149.7

52 Week Range

  • Low 669.80
  • High 1,153.00
₹ 1,149.7
  • Open Price1,133.00
  • Previous Close1,132.95
  • Volume304454

Start SIP in Ipca Laboratories

Start SIP

Ipca Laboratories Share Price

  • Over 1 Month 17.47%
  • Over 3 Month 32.64%
  • Over 6 Month 62.96%
  • Over 1 Year 32.97%

Ipca Laboratories Key Statistics

P/E Ratio 59.3
PEG Ratio -3
Market Cap Cr 29,168
Price to Book Ratio 4.9
EPS 19.2
Dividend 0.2
Relative Strength Index 75.15
Money Flow Index 82.03
MACD Signal 34.14
Average True Range 27.25

Ipca Laboratories Investment Rating

  • Master Rating:
  • Ipca Laboratories has an operating revenue of Rs. 6,679.17 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 12% is healthy, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 11%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 15% and 35% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 56 which is a POOR score indicating inconsistency in earnings, a RS Rating of 72 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 64 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Ipca Laboratories Financials
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 1,6631,4891,4021,4331,4851,4691,168
Operating Expenses Qtr Cr 1,3541,1911,2261,2191,2131,212989
Operating Profit Qtr Cr 309298176214272257179
Depreciation Qtr Cr 61605957555352
Interest Qtr Cr 39311810973
Tax Qtr Cr 83834752777227
Net Profit Qtr Cr 16216785120168144110
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 5,9265,455
Operating Expenses Annual Cr 4,9034,156
Operating Profit Annual in Cr 9121,244
Depreciation Cr 229204
Interest Annual Cr 447
Tax Annual Cr 245217
Net Profit Annual Cr 506871
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 840
Cash from Investing Activity Annual Cr -824
Cash from Financing Annual Activity Cr 426
Net Cash Flow Annual Cr 442
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 5,8775,523
Fixed Assets Annual Cr 2,6022,374
Total Non Current Assets Annual Cr 3,5723,276
Total Current Assets Annual Cr 4,8754,191
Total Assets Annual Cr 8,4477,467
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 232218
ROE Annual % 916
ROCE Annual % 1218
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 1824
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 2,0341,5881,5121,5461,6011,5861,289
Operating Expenses Qtr Cr 1,7131,2801,3311,3301,3401,3171,070
Operating Profit Qtr Cr 321308181216261269219
Depreciation Qtr Cr 90697067646261
Interest Qtr Cr 44311811973
Tax Qtr Cr 88864854777429
Net Profit Qtr Cr 14516377108144143130
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 6,3705,896
Operating Expenses Annual Cr 5,3184,521
Operating Profit Annual in Cr 9271,309
Depreciation Cr 262232
Interest Annual Cr 468
Tax Annual Cr 253225
Net Profit Annual Cr 471884
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 856
Cash from Investing Activity Annual Cr -855
Cash from Financing Annual Activity Cr 427
Net Cash Flow Annual Cr 428
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 5,8425,492
Fixed Assets Annual Cr 2,8542,670
Total Non Current Assets Annual Cr 3,4373,182
Total Current Assets Annual Cr 5,1894,457
Total Assets Annual Cr 8,6267,639
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 233220
ROE Annual % 816
ROCE Annual % 1219
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 1724

Ipca Laboratories Technicals

EMA & SMA

Current Price
₹1,149.7
16.75 (1.48%)
pointer
  • Bullish Moving Average
  • ___
  • 16
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹1,070.05
  • 50 Day
  • ₹1,008.27
  • 100 Day
  • ₹946.66
  • 200 Day
  • ₹900.26
  • 20 Day
  • ₹1,064.74
  • 50 Day
  • ₹993.82
  • 100 Day
  • ₹928.54
  • 200 Day
  • ₹845.63

Ipca Laboratories Resistance and Support

PIVOT
₹1,142.22
Resistance
First Resistance 1,160.48
Second Resistance 1,171.27
Third Resistance 1,189.53
RSI 75.15
MFI 82.03
MACD Single Line 34.14
MACD 39.29
Support
First Resistance 1,131.43
Second Resistance 1,113.17
Third Resistance 1,102.38

Ipca Laboratories Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 316,599 14,069,660 44.44
Week 414,943 18,610,194 44.85
1 Month 387,838 14,272,421 36.8
6 Month 642,692 28,304,165 44.04

Ipca Laboratories Result Highlights

Ipca Laboratories Synopsis

NSE-Medical-Generic Drugs

Ipca Laboratorie is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 5814.62 Cr. and Equity Capital is Rs. 25.37 Cr. for the Year ended 31/03/2023. Ipca Laboratories Ltd. is a Public Limited Listed company incorporated on 19/10/1949 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1949PLC007837 and registration number is 007837.
Market Cap 29,168
Sales 5,986
Shares in Float 13.70
No of funds 223
Yield 0.17
Book Value 4.96
U/D Vol ratio 2.3
LTDebt / Equity 11
Alpha 0.11
Beta 0.39

Ipca Laboratories

Owner NameSep-23Jun-23Mar-23Dec-22
Promoters 46.29%46.29%46.29%46.29%
Mutual Funds 30.23%30.27%29.94%29.79%
Insurance Companies 4.12%4.26%3.61%3.76%
Foreign Portfolio Investors 9.86%10.05%10.58%10.46%
Financial Institutions/ Banks 0.01%
Individual Investors 7.14%6.98%7.26%7.41%
Others 2.36%2.14%2.32%2.29%

Ipca Laboratories Management

Name Designation
Mr. Premchand Godha Chairman & M.D & CEO
Mr. Ajit Kumar Jain Joint Managing Director & CFO
Mr. Pranay Godha Executive Director
Mr. Prashant Godha Executive Director
Mr. Anand T Kusre Independent Director
Mr. Dev Parkash Yadava Independent Director
Dr.(Mrs.) Manisha Premnath Independent Director
Mr. Kamal Kishore Seth Independent Director

Ipca Laboratories Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Ipca Laboratories Corporate Action

Date Purpose Remarks
2023-11-10 Quarterly Results & Interim Dividend
2023-08-10 Quarterly Results
2023-05-29 Audited Results
2023-02-14 Quarterly Results
2022-11-11 Quarterly Results & Interim Dividend
Date Purpose Remarks
2023-11-22 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2022-11-23 INTERIM Rs.4.00 per share(400%)Interim Dividend
2021-11-23 INTERIM Rs.8.00 per share(400%)Interim Dividend
Date Purpose Remarks
2022-01-11 Split Rs.0.00 split from Rs. 2/- to Re. 1/-.

Ipca Laboratories MF Shareholding

Name Amount(cr)
HDFC Balanced Advantage Fund Growth 63,981
ICICI Prudential Balanced Advantage Fund Growth 49,871
HDFC Mid-Cap Opportunities Fund Growth 47,846
Parag Parikh Flexi Cap Regular Growth 44,038
Kotak Emerging Equity Scheme Growth 33,700

Ipca Laboratories FAQs

What is Share Price of Ipca Laboratories ?

Ipca Laboratories share price is ₹1,149 As on 02 December, 2023 | 19:49

What is the Market Cap of Ipca Laboratories ?

The Market Cap of Ipca Laboratories is ₹29168.4 Cr As on 02 December, 2023 | 19:49

What is the P/E ratio of Ipca Laboratories ?

The P/E ratio of Ipca Laboratories is 59.3 As on 02 December, 2023 | 19:49

What is the PB ratio of Ipca Laboratories ?

The PB ratio of Ipca Laboratories is 4.9 As on 02 December, 2023 | 19:49

Q2FY23